BGNE:NSD-BeiGene Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 317.25

Change

+18.04 (+6.03)%

Market Cap

USD 33.26B

Volume

0.25M

Avg Analyst Target

USD 417.25 (+31.52%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BeiGene Ltd (BGNE) Stock Analysis:
Based on the BeiGene Ltd stock forecasts from 3 analysts, the average analyst target price for BeiGene Ltd is USD 417.25 over the next 12 months. BeiGene Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BeiGene Ltd is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, BeiGene Ltd’s stock price was USD 317.25. BeiGene Ltd’s stock price has changed by -30.28 % over the past week, -47.74 % over the past month and +39.09 % over the last year.

About

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classica ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+17.02 (+6.41%)

USD122.24B 18.38 14.64
BNTX BioNTech SE

+22.86 (+8.17%)

USD83.44B 8.87 7.65
REGN Regeneron Pharmaceuticals Inc

+10.09 (+1.61%)

USD68.31B 10.00 7.78
VRTX Vertex Pharmaceuticals Incorpo..

+0.16 (+0.08%)

USD51.82B 24.59 15.60
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.43 (+0.29%)

USD27.56B 55.02 44.86
GMAB Genmab A/S

+1.82 (+4.93%)

USD24.43B 55.83 6.05
ALNY Alnylam Pharmaceuticals Inc

+3.28 (+1.85%)

USD20.49B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
TECH Bio-Techne Corporation

+4.72 (+1.01%)

USD17.92B 107.96 64.40

ETFs Containing BGNE

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.78% 84% B 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.78% 84% B 69% D+
Trailing 12 Months  
Capital Gain 39.09% 84% B 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.09% 84% B 78% C+
Trailing 5 Years  
Capital Gain 1,077.18% 95% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,077.18% 95% A 96% A
Average Annual (5 Year Horizon)  
Capital Gain 82.45% 85% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 82.45% 85% B 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 105.13% 25% F 15% F
Risk Adjusted Return 78.42% 95% A 87% B+
Market Capitalization 33.26B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.75 12% F 14% F
Price / Cash Flow Ratio -25.91 83% B 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -33.98% 74% C 34% F
Return on Invested Capital -58.67% 42% F 15% F
Return on Assets -15.57% 76% C 24% F
Debt to Equity Ratio 4.75% 62% D- 78% C+
Technical Ratios  
Short Ratio 13.85 10% F 5% F
Short Percent 5.88% 36% F 27% F
Beta 0.75 74% C 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector